Abstract: Nucleic acid compositions encoding non-aggregating chromo/fluoroproteins and mutants thereof, as well as the proteins encoded by the same, are provided. The proteins of interest are polypeptides that are non-aggregating colored and/or fluorescent proteins, where the non-aggregating feature arises from the modulation of residues in the N-terminus of the protein and the chromo and/or fluorescent feature arises from the interaction of two or more residues of the protein. Also provided are fragments of the subject nucleic acids and the peptides encoded thereby, as well as antibodies to the subject proteins and transgenic cells and organisms. The subject protein and nucleic acid compositions find use in a variety of different applications. Finally, kits for use in such applications, e.g., that include the subject nucleic acid compositions, are provided.
Type:
Grant
Filed:
November 3, 2006
Date of Patent:
December 28, 2010
Assignee:
Clontech Laboratories, Inc.
Inventors:
Sergey Lukyanov, Konstantin Lukyanov, Yuriy Yanushevich, Alexandr Savitsky, Arcady Fradkov
Abstract: Disclosed herein are sequences, molecules and methods used to suppress the expression of HD genes encoding for huntingtin protein in primates including Macaca mulatta and Homo sapiens. These sequences, molecules and methods aid in the study of the pathogenesis of HD and can also provide a treatment for this disease by reducing HD mRNA without causing death, locomotor impairment or cellular alterations of the Macaca mulatta and Homo sapiens.
Type:
Application
Filed:
August 9, 2006
Publication date:
December 23, 2010
Inventors:
William F. Kaemmerer, Michael D. Kaytor
Abstract: A mammalian cell comprising a recombinant, functional L-threonine 3-dehydrogenase (EC 1.1.1.103; TDH) gene, methods of making, and methods of use.
Abstract: The present invention relates in one embodiment to PAPP-A exosite(s) interactors such as antibodies which bind to a region comprising LNR3 of PAPP-A and efficiently inhibit proteolysis of IGFBP-4, but not -5. The region comprising LNR3 represents a substrate binding exosite, which can be targeted for selective proteolytic inhibition. Accordingly, the present invention relates in one embodiment to differential inhibition of natural protease substrates by exosite targeting.
Type:
Application
Filed:
January 23, 2009
Publication date:
December 9, 2010
Inventors:
Claus Oxvig, Jakob Hauge Mikkelsen, Claus Gyrup Nielsen
Abstract: The Present invention relates to molecules isolated from the nucleic acid that encodes spider web proteins or fragments of these or other derivatives of these. The invention also refers to a chimerical gene and an expression vector containing molecules isolated from the nucleic acid that codes for proteins related to the webs of Nephilengys, Cruentata, Avicularia Juruensis and Parawixia Bistriata spiders. Another embodiment of the present invention are transformed cells containing a chimerical gene or an expression vector of the present invention. Yet another embodiment of the present invention relates to a method for obtaining genetically modified organisms containing inventive chimerical genes or expression vectors and a method for obtaining recombinant proteins from the silks of Nephilengys, Cruentata, Aviculana Juruensis and Parawixia Bistriata spiders. Finally, the invention describes products, such as biofilaments and compositions, using the recombinant proteins of the present invention.
Type:
Application
Filed:
March 13, 2008
Publication date:
December 9, 2010
Applicants:
Empresa Brasileira de Pesquisa Agropecuaria- EMBRAPA, Fundacao Universidade de Brasilia
Inventors:
Elibio Leopoldo Rech Filho, Natalia Cristina Verza Ferreira, Giovanni Rodrigues Vianna, Felipe Rodrigues Da Silva, Francisco Jose Lima Aragao, Luiz Alberto Colnago, Alan Carvalho Andrade, Daniela Matias De Carvalho Bittencourt, Pedro Ismael Da Silva Junior, Betulia De Morais Souto, Luisa De Moraes Madeira, Paulo Cesar Motta
Abstract: Disclosed are nucleic acid-based sensors for measuring the pH of a sample, including cells, regions thereof, and whole organisms. The sensor includes an I-switch that is triggered by protons, and which functions as a FRET-based pH sensor inside living cells and organisms. Also disclosed are compositions and methods for measuring the pH of a specific region of a cell, such as vesicles, the nucleus, mitochondrial matrix, or the Golgi lumen.
Abstract: The invention relates to novel non-human transgenic animals, which upon antigenic stimulation are capable of producing monovalent antibodies binding to a selected antigen, modified heavy chain transgenes, methods for producing the non-human transgenic animals, methods for immunizing the non-human transgenic animals for as well as monovalent antibodies obtainable by such immunization methods.
Type:
Application
Filed:
May 30, 2008
Publication date:
December 2, 2010
Applicant:
GENMAB A/S
Inventors:
Janine Schuurman, Tom Vink, Jan Van De Winkel, Aran Frank Labrijn, Paul Parren, Willem Karel Bleeker, Frank Beurskens, Patrick Van Berkel
Abstract: The present invention provides compositions and methods for studying neuropathy. The compositions and methods provided herein are particularly useful for screening agents of therapeutic and/or diagnostic potential.
Abstract: A knock-out non-human animal, in particular a mouse, carrying a QPCTL knock-out mutation. Additionally, respective cells and cell lines and methods and compositions for evaluating agents that affect QPCTL, for use in compositions for the treatment of QPCTL-related diseases are disclosed.
Abstract: The present invention relates to a combination of DNA segments comprising: (a) a first segment comprising in 5? to 3? or 3? to 5? order: (aa) a promoter; (ab) a first DNA sequence comprising: (i) a DNA sequence giving rise upon transcription to the sense strand of an shRNA molecule; (ii) a transcriptional stop element which is flanked by a first type of recombinase recognition sequences; and (iii) a DNA sequence giving rise upon transcription to the antisense strand of an shRNA molecule; (b) a second segment comprising in 5? to 3? or 3? to 5? order: (ba) a promoter; (bb) a second DNA sequence comprising: (i) a DNA sequence giving rise upon transcription to the sense strand of an shRNA molecule; (ii) a transcriptional stop element which is flanked by a second type of recombinase recognition sequences; and (iii) a DNA sequence giving rise upon transcription to the antisense strand of an shRNA molecule; wherein (i) said first type of recombinase recognition sequences are recognized and recombined by a recombinas
Type:
Application
Filed:
September 17, 2008
Publication date:
November 25, 2010
Applicant:
HELMHOLTZ ZENTRUM MUNCHEN- DEUTSCHES FORSCHUNGZENTRUM FUR GESUNDHEIT UND UMWELT(GMBH)
Inventors:
Ralf Kühn, Wolfgang Wurst, Patricia Steuber-Buchberger
Abstract: This application is in the field of sialic acid chemistry, metabolism, antigenicity, and the production of transgenic non-human mammals with altered sialic acid production. More particularly, this application relates to N-glycolylneuraminic acid (Neu5Gc) being an immunogen in humans, and the production of Neu5Gc-free mammalian products for laboratory and human use.
Type:
Application
Filed:
June 8, 2006
Publication date:
November 18, 2010
Applicant:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Ajit Varki, Anna Maria Hedlund, Dzung Nguyen
Abstract: The invention concerns a method for producing non-human mammal embryos, in particular rabbit by nuclear cloning. The invention also concerns the mammals obtained and their uses.
Type:
Application
Filed:
April 15, 2009
Publication date:
November 18, 2010
Applicant:
Institut National de la Recherche Agronomique
Inventors:
Patrick Chesne, Pierre Adenot, Jean-Paul Renard
Abstract: Disclosed is a method of inducing or modeling a disease associated with pathological tau protein aggregation. The method can be carried out in vitro and animal models, and may be used to screen for therapeutic, prognostic or diagnostic agents.
Type:
Grant
Filed:
January 2, 2002
Date of Patent:
November 16, 2010
Assignee:
WisTa Laboratories Ltd.
Inventors:
Claude Michel Wischik, Janet Elizabeth Rickard, David Horsley, Charles Robert Harrington, Franz Theuring, Karsten Stamer, Claudia Zabke
Abstract: Disclosed herein are a cloned canine and a production method thereof. The method comprises the steps of enucleating the oocyte of a canine to prepare an enucleated recipient oocyte, conducting nuclear transfer into the enucleated oocyte using a canine somatic cell as a nuclear donor cell under optimized conditions so as to prepare a nuclear transfer embryo, and transferring the nuclear transfer embryo into the oviduct of a surrogate mother. The present invention provides a method for producing cloned canines and thus, can contribute to the development of studies in veterinary medicine, anthropology and medical science such as the propagation of superior canines, the conservation of rare or nearly extinct canines, xenotransplantation and disease animal models.
Type:
Application
Filed:
July 26, 2006
Publication date:
November 11, 2010
Applicant:
SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION
Inventors:
Woo Suk Hwang, Byeong Chun Lee, Sung Keun Kang, Min Kyu Kim, Goo Jang, Hyun Ju Oh, Hye Jin Kim, Joung Ju Kim, Shamim Hossein Mohammad, Heru Fibrianto Yuda
Abstract: The invention provides methods and compositions for the treatment of asthma and bronchial inflammation, e.g., as induced by an allergen or toxin. In one aspect, the invention provides inhibitors of “Inducible T Cell Kinase” (ITK) polypeptides and methods of making and using them, e.g., as agents and pharmaceutical compositions to treat asthma. In one aspect, the invention is directed to ITK protein expression and/or activity inhibitors. In one aspect, these ITK protein expression and/or activity inhibitors are used with targeting agents. In one aspect, the ITK protein inhibitors of the invention are used to treat asthma. In one aspect, the invention is directed to ITK protein inhibitors as chimeric proteins comprising fragments or altered or truncated forms of ITK protein, or equivalent. In other aspects ITK protein is joined or fused to another moiety (e.g., a targeting domain) or to an antibiotic.
Type:
Application
Filed:
May 15, 2008
Publication date:
November 11, 2010
Applicant:
San Diego State University Foundation, dba San Diego State University Research Foundation
Abstract: This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of tumor suppressor gene(s) or gene product(s). In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human cancer and methods of their use.
Abstract: This invention is in the field of neurology. Specifically, the invention relates to the discovery and characterization of molecular components that play a role in neuronal demyelination or remyelination. In addition, the invention relates to the generation of an animal model that exhibits hypomyelination. The compositions and methods embodied in the present invention are particularly useful for drug screening and/or treatment of demyelination disorders.
Abstract: The invention provides polypeptides comprising inhibitor of apoptosis protein (IAP) family members, such as BmIAP initially derived from Bombyx mori BmN cells, and nucleic acids encoding them, and methods for making and using these compositions, including their use for inhibiting apoptosis.
Type:
Application
Filed:
July 8, 2010
Publication date:
October 28, 2010
Applicants:
Burnham Institute for Medical Research, The Regents of the University of California
Inventors:
Qihong Huang, John C. Reed, Bruce D. Hammock, Quinn L. Deveraux, Susumu Maeda, Hiroko Maeda
Abstract: The invention concerns a non-human mammal carrying a mutation in the gene coding for the alpha6 subunit of the nicotinic acetylcholine receptor (nAChR), said mutation preventing expression of said nAChR alpha6 subunit in a functional form in the mammal. The invention also concerns synaptosome preparations obtained from said animals and cell cultures obtained by mutation of the alpha6 subunit as defined above.
Type:
Grant
Filed:
March 4, 2003
Date of Patent:
October 26, 2010
Assignee:
Institut Pasteur
Inventors:
Nicolas Champtiaux, Jean-Pierre Changeux, Alain Bessis
Abstract: The present invention relates to a new tumor suppressor, designated Killin. Also described are diagnostic and therapeutic uses of the Killin protein and the killin gene, alone or in combination with traditional cancer therapies.
Abstract: This invention relates to selective activation of the alternative pathway (AP) using anti-Properdin antibodies. Specifically, the invention relates to methods for treating an AP complement-mediated pathology or AP mediated condition in a subject by contacting the subject with an anti-Properdin antibodies. Likewise, properdin knockout transgenic non-human mammals and their use are provided.
Abstract: The instant invention provides an inert DNA sequence having a length of between about 0.5 kb and about 5 kb, wherein said isolated inert DNA sequence does not contain an open reading frame and which is suitable for efficient packaging of expression cassettes comprising a nucleic sequence encoding a therapeutic agent into viral vectors, as well as methods of selecting such inert DNA sequences. The invention also provides DNA constructs and medical composition comprising such inert DNA sequences, and kits and medical systems for delivering such DNA constructs and/or compositions.
Type:
Application
Filed:
April 30, 2008
Publication date:
October 14, 2010
Applicant:
Medtronic, Inc
Inventors:
Michael D. Kaytor, Jennifer M. Heisel, Eric Neal Burright, Jocelyn Clark-Gruel
Abstract: The present invention provides for a recombinant nucleic acid molecule comprising a region of a calcium-calmodulin dependent kinase II? promoter operatively linked to a gene of interest. The region of a calcium-calmodulin dependent kinase II? promoter may comprise an 8.5 kilobase nucleic acid sequence which corresponds to the nucleic acid sequence of ATCC Accession No.: ______, designated pMM281. The present invention also provides a human cell line which has been stably transformed by a recombinant nucleic acid molecule comprising a gene of interest operatively linked to a nucleic acid encoding a calcium-calmodulin dependent kinase II? promoter region which has a nucleotide sequence corresponding to the sequence of ATCC Accession No. ______, designated pMM281. The present invention also provides for a transgenic nonhuman mammal whose germ or somatic cells contain a nucleic acid molecule which encodes a gene of interest under the control of a CaMKII? promoter (ATCC Accession No.
Abstract: The present invention relates to the discovery, identification and characterization of a receptor protein, referred to herein as T1R3, which is expressed in taste receptor cells and associated with the perception of bitter and sweet taste. The invention encompasses transgenic animals and cells that do not express functional T1R3 protein, particularly knock-out animals and cells, and transgenic animals and cells that express a non-native T1R3 protein. Experimental model systems based on these animals and cells can be used to study T1R3-mediated taste transduction and responses of the components of the T1R3 signal transduction pathway to various tastants, furthering our understanding of the molecular biology and biochemistry of taste. Such model systems would also be useful for screening for novel tastants and taste modulators, such as enhancers of desirable flavors, and blockers of undesirable flavors.
Type:
Grant
Filed:
July 15, 2004
Date of Patent:
September 28, 2010
Assignee:
The Mount Sinai School of Medicine of New York University
Inventors:
Robert Margolskee, Minqing Rong, Sami Damak
Abstract: The present invention is directed to various methodologies to make NT a practical procedure for animals, specifically, primates including human and non-human primates. Furthermore, the methods and molecular components provided by the present invention provide a practical means for producing embryos with desired characteristics. In a specific embodiment, the methodology of the present invention comprises introducing nuclei having desired characteristics along with one or more molecular components into an enucleated egg, thus creating a nuclear transfer construct, culturing the egg to produce a viable embryo, transferring the embryo to the oviducts of a female, and producing a cloned animal.
Type:
Application
Filed:
March 29, 2010
Publication date:
September 23, 2010
Inventors:
Gerald P. Schatten, Calvin R. Simerly, Christopher S. Navara
Abstract: The invention relates to a method for cloning in the rat by nuclear transfer. The invention further relates to the rats obtained thus, in the foetal or adult state, as well as use thereof for the production of molecules of interest or as study models.
Type:
Grant
Filed:
August 1, 2008
Date of Patent:
September 21, 2010
Assignee:
Institut National de la Recherche Agronomique
Abstract: The present invention provides a method of treating diabetes by increasing peripheral nesfatin-1. Peripheral nesfatin-1 can be increased by administration of nesfatin-1, conjugated nesfatin-1 that would not penetrate the blood-brain barrier, or plasmin inhibitors. The present invention also provides a method of screening for an agent that would increase peripheral or brain nesfatin-1.
Abstract: The present invention provides pladin (plasma anti-diabetic nucb2 peptide) polypeptide and functional equivalent thereof that are useful for treating diabetes. The present invention provides a method of treating diabetes by administering to a subject nesfatin-1, pladin, or a functional equivalent thereof. The present invention also provides a method of treating diabetes by administering to subject plasmin inhibitors.
Abstract: The present invention provides a hairless transgenic nonhuman animal used in the development of a therapy for dermatitis such as human atopic dermatitis and drug discovery. Specifically, the present invention provides a transgenic nonhuman animal, into which recombinant DNA comprising a heparin-binding EGF gene and a type 2 keratin gene promoter for regulating expression of the above gene has been introduced.
Abstract: The invention concerns the use of a nucleic acid/cationic polymer complex, preferably polyethyleneimine (PEI) for preparing a composition for intraventricular stereotactic screening of stem cells of the brain for preparing a medicine for treating neurodegenerative and/or demyelinating disease. The invention further concerns a method for obtaining an animal whereof the genome of stem cells of the brain are modified by using said complex. The invention also concerns a method for obtaining an animal for screening compounds designed to modify the disposition of stem cells of the brain.
Type:
Grant
Filed:
September 21, 2001
Date of Patent:
September 14, 2010
Assignee:
Centre National de la Recherche Scientifique (CNRS)
Inventors:
Barbara Demeneix, Grégory Lemkine, Giovanni Levi
Abstract: Isolated DNAs encoding the enzyme I-Spoml and its recognition and cutting site are provided. The DNA sequences can be incorporated in cloning and expression vectors, transformed cell lines and transgenic animals. The vectors are useful in gene mapping and site-directed insertion of genes.
Type:
Application
Filed:
January 19, 2010
Publication date:
September 9, 2010
Inventors:
Stefan Pellenz, Bernard Dujon, Alexis Harington, Bernd Schafer
Abstract: A transgenic non-human mammal with a disruption in its IL-21 receptor gene is provided, along with methods of using the transgenic non-human mammal.
Type:
Application
Filed:
January 6, 2010
Publication date:
September 2, 2010
Inventors:
Marion KASAIAN, Matthew WHITTERS, Andrea WURSTER, Mary COLLINS, Deborah YOUNG, Michael GRUSBY
Abstract: One aspect of the present invention is directed to search receptors based on the information of HN signaling pathways in order to find Humanin receptor or Humanin-like polypeptide receptor (HNR), and to reveal a mechanism of promoting or suppressing the intracellular signal transduction for neuroprotecting activity of HN and identify a compound involved in the mechanism. The aspect of the invention is directed to a method for screening of HNR agonist and HNR antagonist, to utilize the screened compound in development of a drug for the treatment of neurodegenerative disease, and to provide an assay system of AD neuronal cell death, and to provide methods for the compulsory expression of HNR gene or knocking-out of intracellular genes.
Type:
Application
Filed:
April 10, 2006
Publication date:
September 2, 2010
Applicants:
Japan Science and Technology Agency, KEIO University
Abstract: The present invention discloses an isolated nucleic acid molecule encoding an ISRAA polypeptide comprising a nucleotide sequence exhibiting at least 70% homology to the sequence represented by the nucleotide sequence SEQ ID No: 1. Also disclosed is a recombinant expression vector comprising said nucleic acid molecule and an isolated polypeptide molecule encoded by said nucleic acid molecule.
Abstract: Disclosed herein are methods and compositions for genome editing of one or more loci in a rat, using fusion proteins comprising a zinc-finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins.
Type:
Application
Filed:
December 3, 2009
Publication date:
August 26, 2010
Inventors:
Xiaoxia Cui, Aron M. Geurts, Fyodor Urnov
Abstract: The invention relates to antibodies and subsequences thereof that specifically bind to poxvirus B5R envelope protein, antibodies and subsequences thereof that specifically bind to pox virus H3L envelope protein, and combinations thereof.
Abstract: The invention provides methods for the production of transgenic animals comprising a recombinant Ig locus, as well as transgenic antibodies derived therefrom. The methods involve meganuclease cleavage-stimulated homologous recombination in mammalian embryos.
Abstract: The present invention relates to the human and murine melanoma inhibitory activity protein-2 (MIA-2) and to the nucleic acids encoding said proteins including a method for producing such proteins by recombinant techniques. The invention also relates to methods for utilizing such proteins for tissue regeneration, tumor treatment including to control the proliferation and differentiation of liver cells in vivo and in vitro. The invention further relates to diagnostic assays including the human and murine antibodies or aptamers and their use in therapy and diagnosis. Further it relates to diagnostic assays applying specific primers for the diagnostic of liver disease.
Type:
Application
Filed:
December 9, 2009
Publication date:
August 19, 2010
Inventors:
Anja Katrin Bosserhoff, Claus Hellerbrand, de Buettner
Abstract: The present invention provides for methods of treating and preventing cardiac hypertrophy. Class I HDACs, which are known to participate in regulation of chromatin structure and gene expression, have generally been considered as pro-hypertrophic in their action. However, the present invention demonstrates that inhibition of certain Class I HDACs should be avoided in the treatment of cardiac hypertrophy, thereby pointing toward selective, and not global, inhibition of Class I HDACs. In particular, the present invention provides for selective inhibition of HDACs 1 and/or 2, and the avoidance of inhibition of HDAC3.
Type:
Application
Filed:
September 29, 2009
Publication date:
August 19, 2010
Inventors:
Eric N. Olson, Lawrence Melvin, Rusty L. Montgomery
Abstract: A prognostic marker for breast cancer and a composition for inducing obesity are provided, wherein said marker and said composition comprise HCCR-1.
Abstract: The present invention provides a mammary gland-specific human erythropoietin expression (hEPO) vector, transgenic animal and method for producing human erythropoietin using the same. The inventive hEPO-expressing transgenic animals express a mammary gland-specific EPO at an extremely higher concentration than the convention method. The hEPO produced from inventive transgenic animals shows better stability and superior physiological activity than those of the same kind of commerally available protein. Therefore, the inventive hEPO-expressing transgenic animals can be effectively used for production of EPO showing a superior physiological activity than the existing EPO.
Abstract: Genetically-modified mammals and immune cells are provided which are capable of producing or secreting detectably-labeled immunoglobulin molecules as a result of genetic modifications of at least one immunoglobulin gene in the genome thereof, such that a fusion polynucleotide encoding a detectable protein or peptide and an immunoglobulin component molecule is present.
Abstract: The invention relates to the production of proteins and other substances of interest in saliva of transgenic animals, particularly in mammals that produce large quantities of saliva, particularly monogastric ruminants, and ovine, caprine and bovine mammals. Preferred embodiments of the invention relate in particular to the production of foreign and modified proteins in the transgenic saliva of these animals, including particularly human fibrinogen, human prothrombin and human thrombin, among others. The invention relates as well to methods, devices, genetic constructs and to transgenic constructs for making the proteins and other substances of interest, to novel saliva and saliva-derived compositions, novel products from the saliva, and to uses of the saliva, saliva-derived compositions and novel products.
Abstract: Methods and compositions are presented for the administration of transposon based vectors to an animal or human to provide gene therapy to the animal or human.
Type:
Application
Filed:
December 24, 2004
Publication date:
August 5, 2010
Inventors:
Richard Cooper, Frederick M. Enright, William C. Fioretti
Abstract: The present invention relates generally to novel molecules capable of, inter alia, modulating apoptosis in mammalian cells and to genetic sequences encoding same. More particularly, the present invention relates to a novel member of the Bcl-2 family of proteins, referred to herein as “Bmf”, and to genetic sequences encoding same and to regulatory sequences such as a promoter sequence directing expression of Bmf. Bmf comprises a BH3 domain which facilitates interaction to pro-survival Bcl-2 family members thereby triggering apoptosis. Bmf is regarded, therefore, as a BH3-only molecule. The molecules of the present invention are useful, for example, in therapy, diagnosis, antibody generation and as a screening tool for therapeutic agents capable of modulating physiological cell death or survival and/or modulating cell cycle entry.
Type:
Application
Filed:
July 7, 2009
Publication date:
August 5, 2010
Applicant:
The Walter And Eliza Hall Institute Of Medical Research
Inventors:
Andreas STRASSER, Hamsa PUTHALAKATH, Andreas VILLUNGER, Leigh COULTAS, Jennifer BEAUMONT, Lorraine Ann O'REILLY, David Ching Siang HUANG
Abstract: A new isoform of manganese superoxide dismutase (MnSOD) and polynucleotides encoding it have been identified. This isoform, MnSOD E3(?), is a splice variant lacking exon 3 of the full length MnSOD. The polypeptide can be expressed using appropriate host cells. Modulation of either the expression of the polynucleotides of the activity of the polypeptide is also described. Furthermore, diagnostic and therapeutic methods have been developed as a consequence of the isolation of the polynucleotides and polypeptides.
Abstract: The present invention provides a transgenic animal model of Alzheimer's Disease designated TgCRND8 as well as a method for making such model, which allows for the characterization of the etiology of the disease as well as for provide a system for the development and testing of potential treatments.
Type:
Grant
Filed:
April 7, 2008
Date of Patent:
August 3, 2010
Assignee:
The Governing Council of the University of Toronto
Inventors:
Peter H. St. George-Hyslop, Paul E. Fraser, David Westaway
Abstract: The present invention concerns the use of PI3K? protein and/or encoding gene for the screening for substances useful in the treatment of cancers, preferably breast cancers. The present invention also concerns a method for the diagnosis of malignant cell growth comprising the measuring the expression of PI3K? gene. The invention concerns also non-human transgenic animals as model study for human pathologies, preferably breast cancer, being transgenic for having altered PI3K? and Neu-T expression.
Abstract: The present invention provides transgenic animal models of Parkinson's disease. More specifically, the present invention provides a transgenic rodent animal containing a nucleic acid molecule which encodes a mutant human LRRK2 protein. The transgenic animal of the present invention recapitulates cardinal Parkinson's disease symptoms and characteristics. The present invention also provides methods of screening for a therapeutic agent useful for treating Parkinson's disease by utilizing such transgenic rodent animal.